Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 8M | 6M | 6M | 1M |
| Gross Profit | 2M | 2M | 1M | 1M | 430K |
| Operating Income | -904K | -4M | -3M | -2M | -3K |
| EBITDA | -884K | -4M | -3M | -2M | -3K |
| Net Income | -896K | -4M | -3M | -2M | -3K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.45
-18.18% today
1Y Change
+454.46%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syra Health Corp. Class A Common Stock (SYRA) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.45 and up 454.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -9.5%, EPS growth of +85.5%, a dividend yield of 0.0%. What stands out right now is revenue -9.5%, EPS +85.5%, free cash flow +84.8% with operating margin -12.5% and ROIC -40.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYRA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYRA Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
-74.9% YoY
FY Net Income
-$3.3K
+99.8% YoY
Free Cash Flow
-$94.5K
+96.0% YoY
Revenue Growth
-9.5%
EPS Growth
+85.5%
Gross Margin
29.8%
Net Margin
-12.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 8M | 6M | 6M | 1M |
| Gross Profit | 2M | 2M | 1M | 1M | 430K |
| Operating Income | -904K | -4M | -3M | -2M | -3K |
| EBITDA | -884K | -4M | -3M | -2M | -3K |
| Net Income | -896K | -4M | -3M | -2M | -3K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 3M | 3K | 100K |
| Total Assets | 3M | 4M | 5M | 2M | 537K |
| Total Liabilities | 675K | 801K | 910K | 2M | 544K |
| Shareholder Equity | 2M | 3M | 4M | 710K | -7K |
| Total Debt | 144K | 452K | 248K | 935K | 343K |
| Net Debt | -1M | -2M | -3M | 931K | 243K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
88K
+96.1% YoY
Capital Expenditures
6K
+94.8% YoY
Free Cash Flow
94K
+96.0% YoY
Key ratios
Gross Margin
29.8%
Operating Margin
-12.5%
Net Margin
-12.4%
ROE
-39.1%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.